The approval process for cancer drugs involves several stages. First, preclinical studies on animals are conducted to assess safety. If successful, the drug moves to clinical trials, which are conducted in three phases to evaluate safety, efficacy, and optimal dosing. Once these trials are completed, the drug sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for review.
